Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2014; 20(40): 14821-14830
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14821
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14821
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
Xing-Chun Wang, Shen Qu, Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, Tongji University, Shanghai 200072, China
Aaron M Gusdon, Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY 10065, United States
Xing-Chun Wang, Huan Liu, Shen Qu, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Author contributions: Wang XC identified the concept and wrote the manuscript; Gusdon AM and Liu H were involved in editing the manuscript; Qu S organized the paper and approved the final version.
Correspondence to: Shen Qu, Professor, Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China. qushencn@hotmail.com
Telephone: +86-21-66302531 Fax: +86-21-66302531
Received: March 25, 2014
Revised: May 14, 2014
Accepted: July 15, 2014
Published online: October 28, 2014
Processing time: 218 Days and 6.4 Hours
Revised: May 14, 2014
Accepted: July 15, 2014
Published online: October 28, 2014
Processing time: 218 Days and 6.4 Hours
Core Tip
Core tip: The findings showed that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may improve liver function, fat content and distribution, lipid metabolism and reduce the activity of inflammatory cytokines and their associated signal transduction pathways. Thus, we review here that GLP-1RAs are a potential method for pharmacologic treatment that can benefit patients with non-alcoholic fatty liver disease and chronic inflammation.